Trials / Completed
CompletedNCT01019772
Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age
A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberix™ Vaccine in Healthy Infants at Two, Four and Six Months of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 217 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- All
- Age
- 49 Days – 84 Days
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate and compare the immunogenicity and safety of LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) to that of Hiberix™ at vaccination in healthy infants at their 2, 4, and 6 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LBVH0101 (Hib vaccine) | |
| BIOLOGICAL | Hiberix™ Vaccine |
Timeline
- Start date
- 2007-07-01
- Completion
- 2008-08-01
- First posted
- 2009-11-25
- Last updated
- 2009-11-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01019772. Inclusion in this directory is not an endorsement.